Pricing Log in Create free account
Friday 6 November 2026 Export NBIX’s income statement to Excel — free account

Neurocrine Biosciences, Inc.

NBIX Healthcare Drug Manufacturers Specialty & Generic

Neurocrine Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.9 billion, up 21.4% from fiscal 2024.

Revenue
+41.2%
EPS
−3.67%
Free cash flow
+79.0%

Quarter to September 2026, against a year earlier

160.47 5.58 −3.36%
Market cap
$16.2B
P/E
23.0×
Fwd P/E
20.6×
Dividend yield
—
F-score
7/9
Altman Z
7.80
Beneish M
−2.64
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Neurocrine Biosciences, Inc. (NBIX) SEC filings, changes and red flags

Red flags

Filings

Form Period Filed What it reports Flags
10-Q Sep 30, 2026 P1I2: 8 added · 1 removed · 13 modified
P2I1A: no comparison — low extraction confidence
8-K Nov 2, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Sep 25, 2026 5.02 Departure or appointment of directors or officers Officer departure
8-K/A May 14, 2026 9.01 Financial statements and exhibits
10-Q Jun 30, 2026 P1I2: 17 added · 6 removed · 26 modified
P2I1A: no comparison — low extraction confidence 		Inventory outpacing revenue
8-K Jul 30, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K May 27, 2026 5.02 Departure or appointment of directors or officers; 5.07 Submission of matters to a vote of security holders
8-K May 14, 2026 1.01 Entry into a material definitive agreement; 2.01 Completion of an acquisition or disposition; 2.03 Creation of a direct financial obligation; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
10-Q Mar 31, 2026
8-K May 5, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Apr 5, 2026 1.01 Entry into a material definitive agreement; 9.01 Financial statements and exhibits
10-K Dec 31, 2025 1: 26 added · 26 removed · 36 modified
1A: 30 added · 5 removed · 75 modified
7: 29 added · 40 removed · 30 modified
8-K Feb 11, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Nov 21, 2025 5.02 Departure or appointment of directors or officers; 9.01 Financial statements and exhibits
10-Q Sep 30, 2025
8-K Oct 28, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Jun 30, 2025
8-K Jul 30, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Mar 31, 2025
8-K May 5, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-K Dec 31, 2024
8-K Feb 6, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Sep 30, 2024
8-K Oct 30, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Jun 30, 2024
8-K Aug 1, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K May 1, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Feb 7, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits

From the company’s filings on sec.gov. Red flags are raised by rules over the filings’ own data and text; they are not investment advice.